electroCore

ECOR

Market cap $50.5M

Ecora Royalties PLC (ECOR:CA) Q4 2025 Earnings Call Transcript

electroCore (ECOR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ROCKAWAY, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 15, 2026.

ROCKAWAY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society.

ROCKAWAY, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in Frontiers in Neuroscience titled “Adjunctive non-invasive vagus nerve stimulation for chronic mild traumatic brain injury with comorbid post-traumatic stress disorder: a post-hoc analysis” by Drs. Michael Ament, Peter Staats, Norianne Theresa Ingram, and Emily Leonard, demonstrating the potential benefits of adjunctive non-invasive vagus nerve stimulation (nVNS) in patients with chronic mild traumatic brain injury (mTBI) and comorbid post-traumatic stress disorder (PTSD).

ROCKAWAY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the issuance of two new U.S. patents that further bolster the Company's already extensive intellectual property portfolio.

Ecora Royalties PLC (ECOR:CA) Q4 2025 Earnings Call Transcript

electroCore, Inc. (ECOR) Q4 2025 Earnings Call Transcript

electroCore, Inc. (ECOR) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.4 per share a year ago.

Record f ull year 2025 net sales of $ 32.0 , an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales